22.08.2018
Evotec AG DE0005664809
DGAP-News: EVOTEC AND NOVO NORDISK FORM STRATEGIC RESEARCH ALLIANCE IN DIABETES AND OBESITY
DGAP-News: Evotec AG / Key word(s): Miscellaneous
EVOTEC AND NOVO NORDISK FORM STRATEGIC RESEARCH ALLIANCE IN DIABETES AND
OBESITY
22.08.2018 / 07:29
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
* THE ALLIANCE BUILDS UPON EVOTEC'S LEADING DRUG DISCOVERY AND DEVELOPMENT
CAPABILITIES IN DIABETES AND RELATED CO-MORBIDITIES
* NOVO NORDISK ACCESSES EVOTEC'S INTEGRATED DISCOVERY AND DEVELOPMENT
PLATFORM TO PROGRESS NEW MOLECULES FROM CONCEPT TO IND INCLUDING
EVOTEC'S INDIGO PLATFORM
Hamburg, Germany, 22 August 2018:
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today
announced a strategic alliance with Novo Nordisk to discover and develop
novel small molecule therapies to treat patients suffering from diabetes and
obesity as well as co-morbidities such as nonalcoholic steatohepatitis
("NASH"), cardiovascular diseases, and diabetic kidney disease.
Evotec will apply its drug discovery platform, especially in ligand-based
design, to seek to design novel, safe and efficacious products to address
diabetes and associated morbidities. Once suitable pre-clinical candidates
are selected, Novo Nordisk will use Evotec's INDiGO platform to move through
pre-clinical studies to enter IND registration.
Dr Mario Polywka, Chief Operating Officer of Evotec, commented: "Novo
Nordisk is one of the largest, most successful Pharma companies in the world
with a proven leadership position in diabetes and obesity. The integration
of our industry-leading discovery and development platform with Novo
Nordisk's deep disease expertise will create a powerful combination that we
hope will create a difference for patients with diabetes or obesity. We very
much look forward to working with such an innovative partner."
Dr Marcus Schindler, senior vice president, Global Drug Discovery, Novo
Nordisk, added: "Evotec is a highly esteemed company in the field of small
molecules and we are very excited about the collaboration. Novo Nordisk is
confident that this will open up new possibilities in small molecule drug
discovery and development targeting diabetes and obesity with the potential
to make a difference for people living with these serious diseases."
No financial details of the alliance were disclosed.
About Diabetes
Diabetes mellitus ("Diabetes") is a chronic incapacitating disease
associated with severe lifelong conditions which require intensive
monitoring and control, such as cardiovascular diseases, kidney diseases,
nerve damage and eye diseases. According to the International Diabetes
Federation, approximately 425 million people worldwide had diabetes in 2017
(2015: 415 million). Concerning the diabetes market volume, approx. $ 727 bn
were spent on the treatment of diabetes in 2017 (2015: $ 673 bn).
About Obesity
Obesity is an excessive fat accumulation that in many cases impairs health
and affects more than 650 million adults worldwide. The condition often
severely reduces the patient's quality of life and is a major risk factor
for many diseases such as cardiovascular diseases, diabetes, musculoskeletal
disorders, and several forms of cancer. According to World Obesity, the
global annual medical cost of treating obesity-related diseases was over $
800 bn in 2017 and is expected to rise to $ 1.2 trn by 2025.
ABOUT NOVO NORDISK
Novo Nordisk is a global healthcare company with 95 years of innovation and
leadership in diabetes care. This heritage has given us experience and
capabilities that also enable us to help people defeat obesity, haemophilia,
growth disorders and other serious chronic diseases. Headquartered in
Denmark, Novo Nordisk employs approximately 43,100 people in 79 countries
and markets its products in more than 170 countries. For more information,
visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient advocacy
groups and venture capitalists. We operate worldwide and our more than 2,400
employees provide the highest quality stand-alone and integrated drug
discovery and development solutions. We cover all activities from
target-to-clinic to meet the industry's need for innovation and efficiency
in drug discovery and development (EVT Execute). The Company has established
a unique position by assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and
expertise in key therapeutic areas including neuronal diseases, diabetes and
complications of diabetes, pain and inflammation, oncology, infectious
diseases, respiratory diseases and fibrosis. On this basis, Evotec has built
a broad and deep pipeline of approx. 100 co-owned product opportunities at
clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has
established multiple long-term alliances with partners including Bayer,
Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi,
Takeda, UCB and others. For additional information please go to
www.evotec.com and follow us on Twitter @EvotecAG.
FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking
statements, which involve a number of risks and uncertainties. The
forward-looking statements contained herein represent the judgement of
Evotec as of the date of this press release. Such forward-looking statements
are neither promises nor guarantees, but are subject to a variety of risks
and uncertainties, many of which are beyond our control, and which could
cause actual results to differ materially from those contemplated in these
forward-looking statements. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any such
statements to reflect any change in our expectations or any change in
events, conditions or circumstances on which any such statement is based.
Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, [email protected]
---------------------------------------------------------------------------
22.08.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard);
Regulated Unofficial Market in Dusseldorf, Hamburg,
Hanover, Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
716231 22.08.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Evotec AG ISIN: DE0005664809 können Sie bei EQS abrufen
Biotechnologie , 566480 , EVT , XETR:EVT